Inside every person's body there is a small furnace. It sits tucked behind the collarbone and along the spine, and it burns fuel not to propel movement but to produce heat. This is brown fat, and unlike the white fat that accumulates around the waist and thighs, it is metabolically active, consuming glucose and lipids to generate warmth in a process called thermogenesis.
For years, brown fat has been understood as something of a curiosity. It existed. It burned calories when activated by cold. And that was roughly where the scientific consensus ended. What was not understood was how brown fat actually assembled the infrastructure it needed to function. The tissue requires a dense network of nerves to receive signals from the brain and blood vessels to deliver fuel and carry away heat. Without those connections, brown fat sits dormant regardless of how much of it a person carries.
Now, a team at NYU College of Dentistry has published research in Nature Communications that answers that question. The work centres on a protein called SLIT3, produced by brown fat cells, and an enzyme called BMP1 that cuts SLIT3 into two separate fragments. Each fragment performs a distinct job. One prompts the growth of new blood vessels. The other guides the expansion of nerve networks. Together, they build the physical groundwork that allows brown fat to operate as a calorie-burning organ rather than simply existing as inert tissue 1.
The Split Signal
The mechanism the researchers describe has the quality of an elegant engineering solution. SLIT3 arrives as a single protein and is immediately divided into two parts that travel to different targets. This split signal, as the researchers call it, keeps blood vessel growth and nerve development tightly coordinated in both space and time. If one system advances without the other, thermogenesis cannot function properly.
To identify the receptor that mediates the nerve side of this process, the team searched for proteins on cell surfaces that would bind to the relevant SLIT3 fragment. They found PLXNA1, a receptor that interacts with one half of the split SLIT3 signal to regulate how nerve cells develop within brown fat tissue. When either SLIT3 or PLXNA1 was genetically removed in mice, the animals became significantly more sensitive to cold and were unable to maintain their body temperature under conditions that normal mice handled without difficulty. Their brown fat, upon examination, lacked the proper nerve architecture and had an inadequate blood vessel network 1.
The significance of the mouse findings became clearer when the researchers looked at human tissue. They examined fat samples from more than 1,500 individuals, including people with obesity. The gene responsible for producing SLIT3 had already been flagged in previous studies as being associated with obesity and insulin resistance. The new analysis suggested that SLIT3 activity may influence fat tissue health, inflammation levels, and insulin sensitivity in people who carry excess weight 1.
"That really got our attention, as it suggests that this pathway could be relevant in human obesity and metabolic health," said Farnaz Shamsi, assistant professor of molecular pathobiology at NYU College of Dentistry and the study's senior author 1.
Why This Matters for Obesity Treatment
Most medications currently available for weight loss operate on a single principle: reduce how much a person eats. GLP-1 agonists such as semaglutide, sold under brand names including Ozempic and Wegovy, work by suppressing appetite and making users feel full sooner. They have proven effective at generating weight loss, but they do nothing to change how many calories the body burns.
Brown fat offers a different conceptual approach. Rather than asking the body to consume less, it asks the body to expend more. During thermogenesis, brown fat draws in glucose and lipids from the bloodstream and burns them as fuel for heat production. In energy balance terms, this is the expenditure side of the equation rather than the intake side. The researchers describe it as a metabolic sink that prevents dietary energy from being stored as white fat 1.
The SLIT3 discovery points to several specific places in this biological machinery where a drug could intervene. A treatment that mimicked or enhanced the split signal that organises blood vessel and nerve growth in brown fat might activate the tissue more effectively in people who currently have dormant or poorly connected brown fat. The SLIT3/PLXNA1 axis specifically, given its role in nerve development, represents a particularly clear target 1.
The Infrastructure Problem
What the research clarifies is that having brown fat is not the same as having functional brown fat. A person may carry a certain amount of brown adipose tissue but if the tissue lacks adequate innervation and vascularisation, it cannot perform thermogenesis efficiently. Just having the cells is not enough. The cells need roads to deliver their supplies and telephone lines to receive instructions.
This helps explain why earlier research on brown fat activation produced mixed results in human trials. Cold exposure and certain medications can stimulate brown fat activity, but the degree of activation may depend heavily on how well-developed the tissue's supporting infrastructure is to begin with. The new findings suggest that future approaches to metabolic health may need to consider not just whether brown fat is present but whether it has the right connections to function.
Brown fat is not evenly distributed throughout the body. The largest deposits are found in the supraclavicular region, around the neck, and along the spine. It is most active in infants, who lack the muscle shivering response that older children and adults use to generate heat, but it does not disappear entirely with age. Adults retain metabolically active brown fat, and its activity can be measured and quantified using PET scans under controlled cold exposure conditions.
The broader context for this research is the growing understanding that obesity is not simply a disorder of overconsumption but also a disorder of energy expenditure. People with obesity often have reduced resting metabolic rates relative to their body size, meaning their bodies burn fewer calories at rest than would be expected. If brown fat can be systematically activated or expanded, it might address the expenditure side of that imbalance in a way that diet and appetite suppression alone cannot.
What Comes Next
The transition from a discovery in a peer-reviewed journal to a viable therapeutic treatment is long and uncertain. The SLIT3 pathway has been identified as a drug target in cell culture and mouse models, but developing a human therapy that safely modifies this pathway in people will require years of additional work. The researchers have laid out the biological mechanism clearly; what remains is the much more difficult process of determining whether modulating that mechanism in humans produces the desired metabolic effects without unacceptable side effects.
There is reason for cautious optimism. The SLIT3 gene has already been linked to human obesity and insulin resistance in previous genetic studies, which means the association is not limited to the laboratory. The new work provides a mechanistic explanation for why that association exists. That is a meaningful step forward from correlation to causation.
For now, the practical implications for most people are limited. Cold exposure, regular physical activity, and adequate sleep remain the evidence-based approaches to supporting metabolic health. But the science of brown fat activation is moving quickly, and the discovery of the SLIT3 split signal represents a meaningful advance in understanding how the body's internal furnace is wired and what it would take to turn it up.